I believe the question has been answered. This is just to say that while it's not my direct area of responsibility in Health Canada, this is something the department looks at.
I believe the response of the witness is consistent with the view of the department in its evaluation, but if it interests the committee, we would be happy to provide additional information through the clerk, if it is felt that the question has not been answered.
Let me very briefly go back to the last question, Mr. Chairman. When we speak of cumulative effects and impacts, one of the things that are important, given that this is new emerging science, is trying to figure out which mixtures matter, what the cumulative impacts are, and the different uses of some of these chemicals we talk about in CEPA. They have many uses—some of them hundreds, literally thousands of uses—that result in different types and intensities of exposure.
I will go back to the point I've been making throughout, and that is about bio-monitoring. Tracking over time the level we are finding in people is going to be exceedingly important. We can do all the studies, but if we don't bio-monitor to see whether the levels are going up or down, we'll be missing a critical element.